Cell-penetrating peptide (CPP) based delivery have provided immense potential<br />for the therapeutic applications, however, most of nonhuman originated CPPs carry<br />the risk of possible cytotoxicity and immunogenicity, thus may restricting to be<br />used. Here, we describe a novel human-derived CPP, denoted hPP10, and hPP10 has<br />cell-penetrating properties evaluated by CellPPD web server, as well as In-Vitro and<br />In-Vivo analysis. In vitro studies showed that hPP10-FITC was able to penetrate<br />into various cells including primary cultured cells, likely through an endocytosis<br />pathway. And functionalized macromolecules, such as green fluorescent protein<br />(GFP), tumor-specific apoptosis inducer Apoptin as well as biological active enzyme<br />GCLC (Glutamate-cysteine ligase, catalytic subunit) can be delivered by hPP10 in<br />vitro and in vivo. Collectively, our results suggest that hPP10 provide a novel and<br />versatile tool to deliver exogenous proteins or drugs for clinical applications as well<br />as reprogrammed cell-based therapy.
Wang, H., Ma, J.-L., Yang, Y.-G., Song, Y., Wu, J., Qin, Y.-Y., … Liu, C.-B. (2016). Efficient therapeutic delivery by a novel cell-permeant peptide derived from KDM4A protein for antitumor and antifibrosis. Oncotarget, 7(31). https://doi.org/10.18632/oncotarget.8682